As dual PI3K/mTOR inhibitors have a comparable poor toxicity profile to pan-PI3K inhibitors, with common adverse events including fatigue, nausea, vomiting and diarrhea, no dual PI3K/mTOR inhibitors have yet advanced for clinical use for any cancer type. The gene discussed is PIK3CB; the disease is cancer.